Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial to Assess the Safety and Immunogenicity of LNP-nCOV saRNA-02, a Self-amplifying Ribonucleic Acid (saRNA) Vaccine, in SARS-CoV-2 Seronegative and Seropositive Uganda Population

NCT04934111 is registered in ClinicalTrials.gov with MRC/UVRI and LSHTM Uganda Research Unit as lead sponsor.

NCT NCT04934111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04934111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial to Assess the Safety and Immunogenicity of LNP-nCOV saRNA-02, a Self-amplifying Ribonucleic Acid (saRNA) Vaccine, in SARS-CoV-2 Seronegative and Seropositive Uganda Population
Lead sponsor
MRC/UVRI and LSHTM Uganda Research Unit
Phase
Phase 1
Overall status
Unknown status
Start date
December 2, 2021
Completion date
December 31, 2022
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19